Ten post jest także dostępny w języku: polski
The European Commission (EC) announced at the end of last week that it had signed a contract to purchase 400 million doses of COVID-19 vaccine. The contract was signed with AstraZeneca. The value of the contract has not been disclosed. It is only known that the EC paid an advance of EUR 336m.
Vaccine purchase agreement
Under the agreement signed, EU Member States will have the option to purchase 300 million doses of Sars-Cov-2 vaccine with the option to purchase 100 million additional doses of the preparation. The contract signed between AstraZeneca and EC is to provide Europeans with fast access to COVID-19 vaccine.
The EC is also in talks with other pharmaceutical companies. Initial talks were concluded with Moderna, Sanofi, Johnson & Johnson and CureVac, among others. We wrote more about the COVID-19 vaccine here.
Potential of AstraZeneca preparation
AstraZeneca is working together with the University of Oxford to develop a preparation for COVID-19. The COVID-19 vaccine has successfully passed Phases I and II of clinical trials, which confirmed its safety and ability to induce an immunological response.
Currently, the development of the AstraZeneca vaccine is undergoing further phase II and III clinical trials. Only after their successful completion will the preparation be able to be approved by the European Medicines Agency as part of the marketing authorisation procedure.